Study objectives: The purpose of this study was to investigate the effect of heavy-ion radiotherapy on pulmonary function in patients with clinical stage I non-small cell lung cancer (NSCLC) patients. Design: Retrospective study. Setting: Research Center Hospital for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan. Patients: From a total of 81 patients who were not candidates for surgical resection due to medical reasons or patient refusal, and who were treated with carbon beam radiotherapy from October 1994 to February 1999, the 52 patients who had completed the repeat overall pulmonary function tests at 6 and 12 months after undergoing heavy-ion radiotherapy were examined. The total heavy-ion irradiation dose ranged from 59.4 to 95.4 photon gray equivalents (GyE), with a mean dose of 76.2 GyE. Interventions and measurement: Pulmonary function was evaluated prior to heavy-ion radiotherapy and at 6 and 12 months after heavy-ion radiotherapy. Comparisons of all pulmonary function indexes between, before, and at 6 and 12 months after heavy-ion radiotherapy were made using repeated-measures analysis of variance using the Dunnett test for post hoc comparison. Results: A statistically significant decrease in FEV 1 and total lung capacity was detected at both 6 and 12 months after the patient had undergone heavy-ion radiotherapy. No significant decreases in other pulmonary function indexes in patients were observed at either 6 or 12 months after heavy-ion radiotherapy. The magnitude of the decrease in all pulmonary function indexes was < 8% at both 6 and 12 months after heavy-ion radiotherapy. Conclusions: These findings suggest that heavy-ion radiotherapy is feasible for stage I NSCLC patients without a severe loss of pulmonary function.
L
ung cancer is common, fatal if left untreated, and responsible each year for more deaths in the United States and Western Europe than colorectal cancer, cervical cancer, and breast cancer combined. 1 In 1998, lung cancer became the leading cause of death from cancer in Japan. 2 Surgical resection is the standard treatment for non-small cell lung cancer (NSCLC) that is diagnosed at an early stage without regional or distant metastases. Surgical therapy in the most favorable subgroup of patients (ie, clinical stage I) produces a 5-year overall survival rate of 50%. 3, 4 However, for elderly persons and/or patients with comorbidities, surgery is not necessarily the best choice for treatment, due to the possibility of subsequent complications. In particular, NSCLC is commonly seen in patients who have a history of extensive smoking of tobacco. Consequently, many patients in whom NSCLC has been diagnosed also have other smoking-related diseases, such as COPD, coronary artery disease, and peripheral vascular disease. Not infrequently, these diseases or other medical illnesses will render a patient medically inoperable, even though definitive resection might be indicated. Although the proportion of patients with early-stage lung cancer who are medically inoperable is unknown, many patients find themselves in this unfortunate situation, because the overall incidence of lung cancer is high.
Conventional radiograph radiotherapy has been utilized for patients with early-stage but medically inoperable lung cancer. In general, local control and survival rates have been inferior to those produced with surgical resection. [5] [6] [7] [8] Some studies 9, 10 have found that delivering higher doses of radiotherapy may enhance survival. However, many of these patients have severe underlying pulmonary disease and delivering high doses of thoracic irradiation often is not possible due to the likelihood of worsening the pulmonary deficiencies that already exist.
Radiotherapy using heavy-ion beams may produce better results than conventional radiotherapy, because of the excellent dose localization and the high linear energy transfer effects on biological responses. 11, 12 These properties also could result in a high cure rate for lung cancer patients without increasing pulmonary complications and without worsening pulmonary morbidity, resulting in better survival rates. However, the effects of heavy-ion beams on pulmonary function in lung cancer patients have not been examined previously.
Thus, the purpose of this study was to investigate the effects of heavy-ion radiotherapy on pulmonary function in stage I NSCLC patients.
Materials and Methods
The institutional review board at the National Institute for Radiological Sciences approved a prospective trial that began enrolling patients in October 1994. The eligibility criteria included histologic confirmation of clinical stage I NSCLC and medical contraindications to surgical resection and/or patient refusal of such treatment.
Pretreatment Evaluation
The evaluation of patients prior to study enrollment included a complete history and physical examination, chest radiograph, contrast-enhanced thoracic CT scans, head MRI, abdominal ultrasound scans, radionuclide bone scans, pulmonary function testing, bronchoscopy, and routine blood work. All diagnoses were established with biopsy specimens obtained by means of bronchoscopy or transthoracic needle biopsy. All patients reviewed and signed an institutional review board-approved, studyspecific consent form prior to enrollment.
Treatment Methods
Carbon beams for radiotherapy were generated by the heavyion medical accelerator in Chiba, Japan. 12, 13 Carbon beams at energy levels of 290, 350, and 400 MeV per nucleon were used for patient irradiation. The treatment schedule consisted of either 18 fractionations over the course of 6 weeks or 9 fractionations over the course of 3 weeks. [13] [14] [15] The mean total dose was 76.2 photon gray equivalents (GyE). The fraction dose ranged from 3.3 to 5.3 GyE in 18 fractions for Ͼ 6 weeks or from 7.6 to 8.8 GyE in 9 fractions for Ͼ 3 weeks. To express the carbon dose compared to the megavoltage photon irradiation, the equivalent radiation dose (expressed in GyE) was defined as the physical dose multiplied by the relative biological effectiveness of the carbon beams, while the clinical relative biological effectiveness was set as 3.0 at the distal region of a spread-out Bragg peak from previous experimental data and from the results of fast-neutron treatment at the National Institute of Radiological Sciences. 12 A primary tumor was the target. Prophylactic, elective node irradiation was not performed. In targeting, a lesion that was visible on a CT scan in the soft tissue was defined as the gross tumor volume. Clinical tumor volume was determined by setting the margin at Ͼ 5 mm outside the gross tumor volume. The planning target volume then was set at 3 mm outside the clinical tumor volume. A three-dimensional treatmentplanning system was used to generate a "beam's-eye view" and to calculate the dose distribution, the dose-volume histogram (DVH), the shape of the aperture, and the bolus. 14 DVH analysis was performed for all patients. A DVH was generated using the computerized three-dimensional treatment-planning system, and it provided a graphic representation of the proportion of a given structure that has received a given dose of irradiation. Lung volumes in which Ͼ 20 GyE (V 20 ) was delivered and those in which Ͼ 40 GyE (V 40 ) was delivered were calculated and used for this analysis. In general, one to four individual carbon-beam portals and a respiratory-gated irradiation system 16 were used.
Pulmonary Function Tests
Pulmonary function was evaluated prior to heavy-ion radiotherapy, and at 6 months and 12 months after heavy-ion radiotherapy. Vital capacity (VC), FVC, FEV 1 , total lung capacity (TLC), functional residual capacity, and residual volume (RV) were measured using a spirometer (System 9; Minato Medical Science; Tokyo, Japan). Pao 2 and Paco 2 were measured using a blood gas analyzer (model ABL520; Radiometer; Copenhagen, Denmark). The diffusing capacity of the lung for carbon monoxide (Dlco) was measured by the single-breath technique. The Dlco values were not corrected for hemoglobin concentration since patients had a stable hemoglobin concentration at 6 and 12 months after undergoing heavy-ion radiotherapy.
Data Analysis
Data from pulmonary function tests are presented as mean Ϯ SD. A comparison of all pulmonary function indexes among those measured before patients underwent heavy-ion radiotherapy and those measured at 6 and 12 months after patients had undergone heavy-ion radiotherapy was made using repeatedmeasures analysis of variance (ANOVA) with the Dunnett test for post hoc comparison only when the results of the ANOVA were significant at p Ͻ 0.05. The correlation between each change in the pulmonary function indexes at 6 and 12 months after patients had undergone heavy-ion radiotherapy and DVH (V 20 and V 40 ) was made using the Spearman correlation coefficient test. Significance was accepted at p Ͻ 0.05. A subjective evaluation also was performed according to the Radiation Therapy Oncology Group (RTOG; for acute lung reaction) and the RTOG/Euro-pean Organization for Research and Treatment of Cancer (for late lung reaction) grading systems. 17 
Results

Patient Characteristics
Among the 81 patients who were treated with carbon beams from October 1994 to February 1999, 52 patients (37 men and 15 women; age range, 54 to 85 years; mean age, 72 years) completed the repeat overall pulmonary function tests at 6 and 12 months after they had undergone heavy-ion radiotherapy. These 52 patients had no evidence of recurrent tumors at 12 months after undergoing heavy-ion radiotherapy. The characteristics of these 52 patients are shown in Table 1 . Transient dyspnea relating to acute pulmonary reaction (RTOG grade II, 2 patients; RTOG grade III, 2 patients) occurred in only 4 of the 52 patients within 6 months, but all of them had fully recovered with no remaining late subjective damage (RTOG/European Organization for Research and Treatment of Cancer grade I or lower).
Changes in Pulmonary Function
The changes in pulmonary function are shown in Figure 1 and Table 2 . The magnitude of the loss of FEV 1 and TLC at 6 months after heavy-ion radiotherapy was 6% (p Ͻ 0.01) and 4% (p Ͻ 0.01), respectively. No significant changes in FVC, VC, Dlco, Pao 2 , or Paco 2 at 6 months after heavy-ion radiotherapy were observed. The magnitude of the loss of FEV 1 and TLC at 12 months after heavy-ion radiotherapy was 7% (p Ͻ 0.01) and 6% (p Ͻ 0.01), respectively. No significant changes in FVC, VC, Dlco, Pao 2 , or Paco 2 at 12 months after heavy-ion radiotherapy were observed. The magnitude of the changes in all pulmonary function indexes was a Ͻ 7% decrease at both 6 and 12 months after heavy-ion radiotherapy.
Changes in Pulmonary Function of Patients With
Underlying COPD: The changes in the pulmonary function indexes of patients with underlying COPD are shown in Table 3 . COPD diagnosis was established by three pulmonologists and was based on medical history, current symptoms, and pulmonary function test results, following the American Thoracic Society guidelines. 18 There were 20 patients with underlying COPD who had an average FEV 1 of 1.22 L (49.9% of the predicted value). No significant changes in any of the pulmonary function indexes including FEV 1 at both 6 and 12 months after heavy-ion radiotherapy were observed. The magnitude of the changes in all pulmonary function indexes was a 2 to 7% decrease at both 6 and 12 months after heavy-ion radiotherapy, except for changes in Dlco. The Dlco values of COPD patients showed no deterioration at either 6 or 12 months after heavy-ion radiotherapy. However, due to the high variability and the technical limits in measuring the Dlco in this very ill patient population, these results should not be overinterpreted.
Changes in Pulmonary Function of Patients With No Pulmonary Comorbidities:
The changes in the pulmonary function indexes of the 15 patients with no pulmonary comorbidities are shown in Table 4 . These 15 patients had no history of pulmonary comorbidity, no findings on chest radiographs and contrast-enhanced thoracic CT scans except for lung cancer, and no impairment of pulmonary function (ie, FEV 1 /FVC ratio, Ͼ 70%; VC, Ͼ 80% of the predicted value). The magnitude of the loss of FEV 1 and TLC at 6 months after heavyion radiotherapy was 8% (p Ͻ 0.01) and 7% (p Ͻ 0.05), respectively. No significant changes in FVC, VC, Dlco, Pao 2 , or Paco 2 at 6 months after heavy-ion radiotherapy were observed. The magnitude of the loss of FEV 1 and TLC at 12 months after heavy-ion radiotherapy was 6% (p Ͻ 0.05) and 7% (p Ͻ 0.01), respectively. No significant changes in FVC, VC, Dlco, Pao 2 , or Paco 2 at 12 months after heavy-ion radiotherapy were observed. The magnitude of the changes in all pulmonary function indexes was a Ͻ 8% decrease at both 6 and 12 months after heavy-ion radiotherapy. Figure 2 shows the correlation between V 20 values and the percentage reduction in FEV 1 and FVC at 6 months after heavy-ion radiotherapy for all patients. No statistically significant correlation was observed between the change in FEV 1 at 6 months after radiotherapy and the V 20 . A statistically significant correlation was observed between the change in FVC at 6 months after radiotherapy and the V 20 . However, the correlation coefficient was low (r ϭ 0.31; p ϭ 0.03). Except for a correlation be- Figure 1 . Changes in pulmonary function test values before patients underwent heavy-ion radiotherapy, and at 6 months and 12 months after they had undergone heavy-ion radiotherapy. Statistically significant decreases in FEV 1 and TLC at both 6 months and 12 months after heavy-ion radiotherapy were observed, compared with the values before radiotherapy. F ϭ mean values of each pulmonary function index; vertical bars, 95% confidence intervals. 6 mo ϭ 6 months after heavy-ion radiotherapy; 12 mo ϭ 12 months after heavy-ion radiotherapy.
Correlation Between Changes in Pulmonary Function Indexes and DVH
tween the change in FVC at 6 months after radiotherapy and the V 20 , all correlations between changes in pulmonary function test values at 6 and 12 months after patients had undergone heavy-ion radiotherapy and both the V 20 and V 40 values had r values of Ͻ 0.25 and nonsignificant p values.
Discussion
One of the aims of radiotherapy is to concentrate a uniform prescribed dose on the target volume, while minimizing the irradiation of the surrounding healthy tissue. It has been recognized that heavy-ion beams may have an advantage in this regard, because their point of maximum energy deposition is at the end of their range (ie, at the Bragg peak), with less scattering taking place than with conventional radiotherapy. 11, 12 In addition to these favorable properties, new technologies, such as the three-dimensional irradiation technique 19 and a respiratory-gated irradiation technique, have been developed that achieve better dose distribution of carbon beams and reduce the margin of moving targets due to breathing, which allows irradiation to be synchronized with a patient's respiration. In a test of this gated system, the target margin along the body axis was decreased to 5 to 10 mm, even though the target moved two or three times. 16 Various previous reports have analyzed the functional loss in pulmonary function after lung resection. Lobectomy causes reductions in lung volume of 15 to 20%, as determined in previous studies. 20 -23 A direct comparison of the loss in pulmonary function after heavy-ion radiotherapy between our results and those obtained after lung resection in previous studies is difficult to perform, due to differences in initial pulmonary function and the time points of analysis. Although a prospective randomized study is required if these important issues are to be addressed, based on our observations the overall changes in pulmonary function after patients undergo heavy-ion radiotherapy are not greater than those after they undergo lung resection. It is especially noteworthy that no significant change was observed in the pulmonary function of COPD patients after heavy-ion radiotherapy. Although several authors have suggested that a wide spectrum of inconsistent changes in pulmonary function results from thoracic radiotherapy, 24 -28 in general, a major impairment in pulmonary function after conventional radiotherapy is a restrictive ventilatory disorder consisting of decreases in FVC and TLC, which indicate a loss of lung parenchyma and/or a stiffening of the chest wall. The deterioration in FEV 1 seems to be a reflection of the loss of lung volume rather than an indication of radiation-induced airway obstruction. In contrast to the change in lung volume, Dlco seems to be the most sensitive and most predictive indicator of radiation-induced lung damage, thus indicating that a loss or thickening of the alveolocapillary membrane is the major factor responsible for the decline in pulmonary function. 25, 27 Abratt et al 27 reported that Dlco values were reduced by 14% and 13%, respectively, of the initial value at 6 months and 12 months after conventional radiotherapy. Choi et al 28 reported that a loss of pulmonary function as the result of thoracic radiotherapy was closely related to the degree of pulmonary reserve before radiotherapy and that patients with FEV 1 values Ͼ 50% of those predicted showed a statistically significant 16 to 28% decrease in pulmonary function 10 to 12 months after undergoing thoracic radiotherapy. However, the magnitude of the changes in all pulmonary function indexes was small for patients with FEV 1 values Ͻ 50% of those predicted. Our results showed that the magnitude of the changes in all pulmonary function indexes decreased by Ͻ 8% at both 6 and 12 months after heavy-ion radiotherapy for both patients with no pulmonary comorbidities and patients with underlying COPD. In particular, the loss of Dlco caused by heavy-ion radiotherapy showed no significant statistical change at either 6 or 12 months after heavy-ion radiotherapy. A direct comparison between the overall changes in pulmonary function after heavy-ion radiotherapy with those after conventional radiotherapy in previous studies is difficult because the underlying pulmonary comorbidity of subjects, the clinical stage of subjects, treatment volumes, radiation dosages, and the time points of analysis have been quite different. This study was not a prospective, randomized, case-control study, which is the type of study that is generally required to address whether or not the loss in pulmonary function caused by heavy-ion radiotherapy is less than the loss in pulmonary function caused by conventional radiotherapy. However, our observations suggest that heavy-ion radiotherapy, despite administering a significantly higher total radiation dose, is feasible for stage I NSCLC patients without a severe loss of pulmonary function after undergoing heavy-ion radiotherapy.
Marks et al 29 reported a relationship between the percentage reduction in pulmonary function and DVH. However, we were unable to detect any correlation between changes in pulmonary function indexes at 6 and 12 months after heavy-ion radiotherapy and both V 20 and V 40 values, except for a correlation between the change in FVC at 6 months after radiotherapy and the V 20 values, which had a low correlation coefficient (r ϭ 0.31) anyway, making it difficult to relate changes in pulmonary function to DVH. This might be due to the small irradiated volume seen in the treatment of patients with stage I NSCLC in addition to the properties of heavy-ion beams. In the present study, the mean entire DVH was 0.41 L (11.3% of the whole-lung volume), the mean V 20 was 0.21 L (5.8% of wholelung volume), and the mean V 40 was 0.11 L (3.0% of whole-lung volume). Further study to develop methods of predicting the changes in pulmonary function following heavy-ion radiotherapy is required.
In conclusion, the magnitude of the loss in pulmonary function was Ͻ 8% at both 6 and 12 months after heavy-ion radiotherapy. Our study suggests that heavy-ion radiotherapy is feasible for stage I NSCLC patients without severe loss of pulmonary function.
